OncoSil Medical Ltd (AU:OSL) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OncoSil Medical Ltd announced significant progress in clinical trials for pancreatic cancer treatments, achieving 50% recruitment in both the TRIPP-FFX and PANCOSIL trials. The TRIPP-FFX trial has now randomized 40 patients to test the OncoSil™ device with standard chemotherapy, while the PANCOSIL trial treated its 10th patient with the device for non-progressive pancreatic cancer. Both milestones mark the company’s advancement towards validating the OncoSil™ device’s broader clinical applications.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.